What were the primary drivers of revenue growth in the first nine months of 2004?

Revenue growth was primarily driven by the full inclusion of Pharmacia's results following its acquisition in April 2003, combined with strong sales from established products like Lipitor, Norvasc, and Celebrex, and the favorable impact of foreign currency exchange rates.

How has the acquisition of Pharmacia impacted Pfizer's financial performance?

The acquisition of Pharmacia significantly impacted Pfizer's financial performance by contributing to revenue growth through the full nine-month period in 2004 compared to approximately 5.5 months in 2003. However, it also resulted in substantial merger-related costs and restructuring charges during the integration process.

What is Pfizer's strategy regarding products facing patent expirations and generic competition?

Pfizer is actively managing the impact of patent expirations by aggressively pursuing patent infringement suits, launching its own generic versions of key products through its subsidiary Greenstone Ltd., and focusing on the growth of its in-line products and newly launched medicines.

What is the company's approach to managing its product portfolio and divesting non-core assets?

Pfizer continuously evaluates its businesses for strategic fit. During this period, the company divested several non-core businesses and product lines, including its in-vitro diagnostics testing business, surgical ophthalmic business, and certain European generic pharmaceutical businesses, classifying these as discontinued operations.

PFE 10-Q Quarterly Report Q3 FY2004 — Revenue, Net Income, EPS

Summary

Pfizer Inc. reported strong financial results for the nine months ended September 26, 2004. Revenues increased significantly to $37.6 billion, driven by the full inclusion of Pharmacia's operations following its acquisition in April 2003 and robust performance from key products like Lipitor, Norvasc, and Celebrex. Net income rose substantially to $8.5 billion, reflecting improved operational efficiency and the integration of Pharmacia. The company continued its strategic portfolio management by divesting non-core assets, including diagnostics, surgical ophthalmic, and certain consumer healthcare products, which were recognized as discontinued operations. Pfizer also made significant investments in research and development, while also managing integration and restructuring costs associated with the Pharmacia acquisition. The company's strong cash flow generation supported robust share repurchase programs and dividend payments, reinforcing its commitment to shareholder returns.

Key Highlights

1Revenues for the first nine months of 2004 increased by 22% to $37.6 billion, largely due to the full integration of Pharmacia and strong performance from top-selling drugs.
2Net income surged to $8.5 billion for the nine months ended September 26, 2004, a significant increase from $3.3 billion in the prior year period.
3The company announced a new $5 billion share-purchase program, signaling continued confidence and commitment to returning capital to shareholders.
4Significant restructuring and integration costs related to the Pharmacia acquisition were incurred, impacting the current period's expenses but aimed at long-term efficiencies.
5Pfizer continued to divest non-core assets, reporting the sale of several businesses and product lines classified under discontinued operations.
6The company is actively managing patent expirations and generic competition for key products, such as Neurontin, and has launched generic versions through its subsidiary, Greenstone.
7Strategic acquisitions, such as Esperion Therapeutics for $1.3 billion, were completed to bolster the drug pipeline, particularly in cardiovascular disease.

PFIZER INC Quarterly Report for Q3 Ended Sep 26, 2004

Summary

Key Highlights

Frequently Asked Questions